This review systematically summarizes recent advances in nanozyme-mediated regulation of the TME and aims to provide a theoretical basis and research perspectives for the further study, rational design, and translational application of nanozymes in cancer therapy.
Abstract
The tumor microenvironment (TME) plays a central regulatory role in malignant tumor progression and therapeutic resistance, and its complexity and dynamic heterogeneity markedly limit the efficacy of current treatment strategies. Therefore, the development of novel functional materials capable of effectively remodeling the TME and alleviating immunosuppression and therapeutic tolerance has become an important research direction in cancer therapy. In recent years, nanozymes, as a class of nanomaterials with enzyme-mimicking catalytic activity, have shown broad potential in TME intervention and the enhancement of cancer therapy owing to their excellent physicochemical stability, tunable structural properties, and multiple biomimetic enzyme-like activities. This review systematically summarizes recent advances in nanozyme-mediated regulation of the TME. First, the basic concepts, catalytic properties, and functional classifications of nanozymes are introduced. Subsequently, the mechanisms by which nanozymes remodel the TME and enhance cancer therapy are discussed from the key dimensions of the redox microenvironment, metabolic microenvironment, and immune microenvironment. Finally, the major challenges, barriers to clinical translation, and future development directions in this field are highlighted. This review aims to provide a theoretical basis and research perspectives for the further study, rational design, and translational application of nanozymes in cancer therapy.
Metal ions serve as key regulators of the dynamic equilibrium within the tumor microenvironment (TME). In recent years, the TME has emerged as a central regulatory hub for tumor initiation, progression, and metastasis; its complexity has become both a frontier and a major challenge in oncology research. Current therapi...
Yan-Na Bi, Ya-Ting Zhao, Yan-Lei Ge et al.· Cancer Letters· 0 citations
Acidity, hypoxia, redox imbalance, and altered enzyme activity in the tumor microenvironment (TME) can be used to regulate nanocarrier structure and drug release. However, these conditions vary among tumors and across regions within individual tumors and overlap with certain normal physiological and inflammatory proces...
Xiu-Lin Wen, Yong-Xin Jiang, H. Yang et al.· Journal of Nanotheranostics· 0 citations
The development and drug resistance of breast cancer are closely associated with the heterogeneity of the tumor microenvironment (TME). Immunosuppressive cells, activated matrix components, abnormal vascular networks, and metabolic reprogramming within the TME collectively create a niche that promotes tumor survival. D...
Yan-Cai Liu, Yan-Ran Yang, Jiang-Long Wang et al.· Natural Products and Biopros...· 0 citations
The lack of clear identification or understanding of the key perpetrators activating the tumor microenvironment (TME) impedes development of TME-modulating therapeutic strategies that could overcome the challenges associated with tumor growth, metastasis, and therapy resistance. Here, we report the development of a h...
Prasanta Panja, S. K. Gulla, Yu-Shan Zhang et al.· ACS Nano· 0 citations
Melanoma remains a major therapeutic challenge in dermatologic oncology because of its aggressive nature and high mortality rate, with traditional therapeutic approaches exhibiting significant limitations in efficacy. Although nanodrug delivery systems (NDS) present a promising paradigm to overcome existing therapeutic...
Han-Qi Wang, Chen-Yu Sun, Han-Lin Wang et al.· Journal of drug targeting (P...· 0 citations
Dual-atom nanozymes (DAzymes) provide a new research strategy for regulating catalytic reaction pathways and redox homeostasis in tumor microenvironments (TMEs) by constructing adjacent metal active centers with specific coordination environments. Compared to traditional nanoparticle nanozymes and single-atom nanozymes...
Cong Lu, Wen-Xia Wang, Jie Chang et al.· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.